新型冠状病毒肺炎:高凝、血栓形成及抗凝  

COVID-19:hypercoagulability,thrombosis and anticoagulation

作　　者：王同生[1] 苏秀丽[1] 高鹏飞 褚旭 邱家勇 毛毅敏[1] WANG Tongsheng;SU Xiuli;GAO Pengfei;CHU Xu;QIU Jiayong;MAO Yimin(Department of Respiratory Diseases,the First Affiliated Hospital,and College of Clinical Medicine of He'nan University of Science and Technology,Luoyang 471003,China)

机构地区：[1]河南科技大学第一附属医院呼吸与危重症医学科,河南科技大学临床医学院,河南洛阳471003

出　　处：《实用医学杂志》2021年第7期835-838,共4页The Journal of Practical Medicine

基　　金：洛阳市科技局疫情防控应急科研攻关项目(编号:2020YZ20)。

摘　　要：新型冠状病毒肺炎(COVID-19)是由新型冠状病毒(SARS-CoV-2)引起的,其特征是炎症反应过度表达。SARS-CoV-2可触发COVID-19患者产生高凝和血栓形成,50%重症患者合并有高凝状态。高达40%的COVID-19患者合并有深静脉血栓形成(deep veinthrombosis,DVT)和肺栓塞(pulmonary thrombo-embolism,PTE),推荐应用低分子肝素(LMWH)预防性抗凝治疗。LMWH除了抗凝作用外,还具有非抗凝作用,如能减少白细胞介素-6(IL-6)释放以及抑制淋巴细胞增加,可以延缓或阻断炎症"细胞因子风暴"。Coronavirus Disease 2019(COVID-19)is caused by the new coronavirus SARS-CoV-2 and is characterized by an exaggerated inflammatory response.SARS-CoV-2 can trigger coagulopathy and thrombosis in patients with covid-19.In severe cases,50%of the patients had coagulopathy.Up to 40%of patients still have deep vein thrombosis(DVT)and pulmonary embolism(PTE).Low molecular weight heparin(LMWH)is recommended as prophylactic anticoagulant therapy,Besides the Anticoagulant effect of LMWH,nonanticoagulant properties such as the reduction in interleukin 6 release and increasing the number of Limba cells,it can delay or block the inflammatory “cytokine storm”.

关 键 词：新型冠状病毒 新型冠状病毒肺炎 高凝 血栓形成 抗凝 

分 类 号：R563.1[医药卫生—呼吸系统] R511[医药卫生—内科学]